Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| ANTX | An2 Therapeutics | $5.30 | $2.45 | 85.97% | 57.6M | $78M | $1.00$6.91 |
| HIMZ | Tidal Trust II - Defiance Daily Target 2x Long Hims ETF | $2.03 | $0.91 | 81.25% | 175.9M | - | $0.88$55.77 |
| DTCK | Davis Commodities | $2.49 | $1.06 | 74.13% | 35.4M | $39M | $1.32$137.80 |
| RLMD | Relmada Therapeutics | $7.01 | $2.56 | 57.53% | 42.7M | $326M | $0.24$7.41 |
| CAMP | Camp4 Therapeutics | $6.28 | $2.08 | 49.41% | 5.9M | $218M | $1.31$7.75 |
| XENE | Xenon Pharmaceuticals | $62.62 | $20.68 | 49.31% | 641.2K | $3.5B | $26.74$62.74 |
| HIMS | Hims & Hers Health | $22.16 | $6.42 | 40.79% | 173.7M | $3.6B | $13.74$70.43 |
| NERV | Minerva Neurosciences | $8.00 | $1.99 | 33.11% | 581.9K | $260M | $1.15$12.46 |
| EPSM | Epsium Enterprise | $2.30 | $0.56 | 32.18% | 78.5K | $23M | $1.04$155.00 |
| RNAC | Cartesian Therapeutics | $8.95 | $2.10 | 30.66% | 27.8K | $178M | $5.98$18.80 |
| ATRA | Atara Biotherapeutics | $6.74 | $1.57 | 30.37% | 71.9K | $37M | $3.92$19.15 |
| PIII | P3 Health Partners | $2.89 | $0.66 | 29.37% | 197.3K | $7.3M | $1.52$11.30 |
| TURB | Turbo Energy | $4.87 | $1.09 | 28.84% | 23.4M | $42M | $0.57$20.45 |
| PLYX | Polaryx Therapeutics | $3.52 | $0.78 | 28.47% | 754.8K | $130M | $2.20$48.91 |
| DDD | 3D Systems | $2.51 | $0.55 | 28.06% | 10.2M | $252M | $1.32$3.80 |
| BIRD | Allbirds | $3.13 | $0.65 | 26.21% | 3.7K | $20M | $2.42$12.85 |
| QURE | uniQure | $17.97 | $3.70 | 25.93% | 601K | $879M | $7.76$71.50 |
| BEG | Themes ETF Trust - Leverage Shares 2x Long Be Daily ETF | $32.43 | $6.29 | 24.05% | 50.6K | - | $10.89$50.61 |
| PURR | Hyperliquid Strategies | $5.33 | $1.00 | 22.98% | 8.1M | $537M | $3.01$5.78 |
| DNTH | Dianthus Therapeutics | $79.23 | $14.03 | 21.52% | 4.6M | $2.8B | $13.37$84.86 |
| FOFO | Hang Feng Technology Innovation | $4.17 | $0.73 | 21.22% | 38.8K | - | $2.86$68.00 |
| LSTA | Lisata Therapeutics | $5.04 | $0.86 | 20.57% | 447K | $37M | $1.81$5.06 |
| CRCG | Themes ETF Trust - Leverage Shares 2x Long Crcl Daily ETF | $4.15 | $0.68 | 19.60% | 33.2M | - | $0.95$20.92 |
| RGNX | Regenxbio | $10.33 | $1.68 | 19.42% | 109.6K | $438M | $5.04$16.19 |
| KC | Kingsoft Cloud | $14.30 | $2.31 | 19.27% | 167.6K | $3.5B | $10.29$19.57 |
| EEIQ | EpicQuest Education Group International | $2.74 | $0.44 | 19.13% | 116.7K | $3.4M | $2.21$27.84 |
| AXTI | AXT | $38.56 | $6.19 | 19.12% | 8.6M | $1.8B | $1.13$47.03 |
| CRBP | Corbus Pharmaceuticals | $9.52 | $1.51 | 18.85% | 21.8K | $141M | $4.64$20.56 |
| DYN | Dyne Therapeutics | $17.66 | $2.80 | 18.81% | 192.9K | $2.5B | $6.36$25.00 |
| VRTL | GraniteShares ETF Trust - GraniteShares 2x Long Vrt Daily ETF | $117.21 | $18.32 | 18.52% | 207.7K | - | $7.57$119.89 |
| SLDB | Solid Biosciences | $7.99 | $1.24 | 18.37% | 148.9K | $526M | $2.41$8.15 |
Related Articles
Featured Article
Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy?
Geoffrey Seiler|Mar 9, 2026
Hims & Hers stock traded more than 40% higher after the deal was announced.
Hims & Hers Stock Pops 40%: Everything You Need to Know
Travis Hoium|Mar 9, 2026
Hims & Hers shares are up over 40% on Monday after announcing a deal with Novo Nordisk.
Down 70% Over the Past Year, Can Hims & Hers Health Stock Bounce Back?
Geoffrey Seiler|Feb 27, 2026
The company is looking toward international markets to boost its growth.
Hims & Hers HUGE Acquisition News!
Travis Hoium|Feb 19, 2026
Hims & Hers is acquiring Eucalyptus and spreading its wings internationally.
Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?
Bram Berkowitz|Feb 9, 2026
Hims & Hers could face difficulty in the future in selling copycat GLP-1 drugs.
Hims & Hers Takes On Novo Nordisk: What We Know Right Now
Travis Hoium|Feb 5, 2026
Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering
Travis Hoium|Feb 4, 2026
Hims & Hers is moving beyond prescriptions to preventative testing.
Stocks to Love in 2026
Motley Fool Staff|Jan 11, 2026
Are you looking for investment opportunities in 2026?
1 Small-Cap Stock I'd Buy Before GLBE in 2026
Marc Guberti|Jan 8, 2026
Global-E Online is a small company trying to carve out a niche in the competitive e-commerce space, while AXT is a small semiconductor player that already has a lead in an emerging opportunity.
Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip?
Parkev Tatevosian, CFA|Nov 26, 2025
The healthcare industry is ripe for disruption.
